Investor Value Proposition

Trillium is developing the next-generation of cancer immunotherapies. Our lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a "do not eat" signal to macrophages. High expression of CD47 by tumor cells has been correlated with more aggressive disease and poor survival. SIRPαFc is initially being developed as a therapy for acute myeloid leukemia but also holds promise as a treatment for other hematological and solid tumors.

Recent Presentations

Thumb Date Download
Nov 18, 2017 SNO 2017 Abstract 4329 684 KB
Sep 26, 2017 Q3 2017 Corporate Presentation 2.87 MB
Jun 05, 2017 2017 ASCO Annual Meeting 415 KB
Apr 03, 2017 AACR 2017 Abstract #2646 9.96 MB
Apr 03, 2017 AACR 2017 Abstract #2653 720 KB

Investor FAQ

Where can I find the current share price?


The current share price can be found by searching for the ticker symbol “TRIL” at and at


Email Address: *
First Name:
Mailing Lists

Enter the code shown above.

Powered By Q4 Inc.